| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 03/21/2002 | US20020035121 Aryl fused substituted 4-oxy-pyridines |
| 03/21/2002 | US20020035120 Oxo-imidazopyridine-carboxamides |
| 03/21/2002 | US20020035114 Substituted dimeric compounds |
| 03/21/2002 | US20020035113 Piperidine, tetrahydropyridine and piperazine derivatives, their preparation and use |
| 03/21/2002 | US20020035110 Treatment or prevention of disorders of the central nervous system, cardiovascular disorders, gastrointestinal disorders, diabetes insipidus, and sleep apnea |
| 03/21/2002 | US20020035105 Composition and method combining an antidepressant with an NMDA receptor antagonist, for treating neuropathic pain |
| 03/21/2002 | US20020035104 Integrin receptor inhibitors |
| 03/21/2002 | US20020035102 Azetidine derivatives, their preparation and medicaments containing them |
| 03/21/2002 | US20020035094 Substituted pyridine compounds and methods of use |
| 03/21/2002 | US20020035083 CRF2 ligands in combination therapy |
| 03/21/2002 | US20020035077 Pyrrolo[2,3-d]pyrimidine nucleoside analogs |
| 03/21/2002 | US20020035068 Administering 2,3:4,5-bis-O-(1-methylethylidene)-B-D-fructopyranose sulfamate or derivative |
| 03/21/2002 | US20020035066 Methods to improve neural outcome |
| 03/21/2002 | US20020035059 For achieving circadian rhythm phase-shifting effect in mammal |
| 03/21/2002 | US20020035057 Treatment of movement disorders by administration of 5-hydroxytryptamine receptor/alpha2 adrenergic receptor antagonist compositions |
| 03/21/2002 | US20020034787 Nucleotide sequences coding polypeptides for use in treatment of wounds, burns, ulcers, nervous system disorders and tumors |
| 03/21/2002 | US20020034779 Novel argS |
| 03/21/2002 | US20020034778 Peptide; for use in drug screening; for use as a diagnostic tool; for use in the treatment of nervous system disorders |
| 03/21/2002 | US20020034764 Diarylsulfonylurea binding proteins |
| 03/21/2002 | US20020034534 Receptor loading dosage form containing therapeutic agent and extended-release dosage form containing therapeutic agent administered concurrently |
| 03/21/2002 | US20020034513 MHC complexes and uses thereof |
| 03/21/2002 | US20020034393 Vector |
| 03/21/2002 | DE10045112A1 Verwendung von Indolderivaten zur Behandlung von Erkrankungen des zentralen Nervensystems The use of indole derivatives for the treatment of diseases of the central nervous system |
| 03/21/2002 | DE10045059A1 Therapeutische Kombination von Liponsäure und Konjuensäuren zur Behandlung diabetischer Störungen The therapeutic combination of lipoic acid and conjugated fatty acids for the treatment of diabetic disorders |
| 03/21/2002 | DE10045047A1 Arzneimittel enthaltend aktiviertes Antithrombin III Medicines containing activated antithrombin III |
| 03/21/2002 | DE10044905A1 (2-Azabicyclo[2.2.1]hept-7-yl)methanol-Derivate als nikontinische Acetylcholinrezeptor Agonisten (2-azabicyclo [2.2.1] hept-7-yl) methanol derivatives as nikontinische acetylcholine receptor agonists |
| 03/21/2002 | CA2742411A1 Pyridazinone and triazinone compounds and use thereof as pharmaceutical preparations |
| 03/21/2002 | CA2422774A1 Remedies for amyotrophic lateral sclerosis |
| 03/21/2002 | CA2422586A1 Methods and compositions relating to hydrogen peroxide and superoxide production by antibodies |
| 03/21/2002 | CA2422376A1 Isoxazoles and their use as inhibitors of erk |
| 03/21/2002 | CA2422288A1 Novel mammalian receptor genes and uses |
| 03/21/2002 | CA2422246A1 Methods and compositions for the treatment and prevention of sexual dysfunction |
| 03/21/2002 | CA2422229A1 Calcium binding proteins |
| 03/21/2002 | CA2422095A1 Tweak receptor agonists as anti-angiogenic agents |
| 03/21/2002 | CA2422076A1 Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination |
| 03/21/2002 | CA2422055A1 Ligands for monoamine receptors and transporters, and methods of use thereof (neurotransmission) |
| 03/21/2002 | CA2422044A1 Nitrogen-containing compounds and their use as glycine transport inhibitors |
| 03/21/2002 | CA2421279A1 2-amino-2-alkyl-3 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors |
| 03/21/2002 | CA2421234A1 Interferon-alpha induced gene |
| 03/21/2002 | CA2420504A1 Muteins of the cgrp 1-7 peptide fragment and use thereof as nicotinic neuronal receptor enhancers |
| 03/21/2002 | CA2420450A1 2-amino-2-alkyl-3 hexenoic and hexynoic acid derivatives useful as nitric oxide synthase inhibitors |
| 03/21/2002 | CA2418720A1 Caspase inhibitors and uses thereof |
| 03/20/2002 | EP1188747A1 Phenoxypropylamine compounds |
| 03/20/2002 | EP1188445A1 Drug composition containing lecithin-modified superoxide dismutase |
| 03/20/2002 | EP1188438A1 Pharmaceutical composition for preventing or treating a disease associated with an excess of Il-12 production |
| 03/20/2002 | EP1188437A2 Beta-hydroxybutyric acid or acetoacetic acid or salts or esters therof for use in improving cerebral function |
| 03/20/2002 | EP1188056A1 Use of gabapentin in assays to identify gabab receptor modulators |
| 03/20/2002 | EP1187931A1 49 human secreted proteins |
| 03/20/2002 | EP1187923A1 Apoptosis inhibition by adenovirus e3/6.7k |
| 03/20/2002 | EP1187908A1 42 human secreted proteins |
| 03/20/2002 | EP1187843A1 Angiogenic proteins and uses thereof |
| 03/20/2002 | EP1187842A1 Human tumor necrosis factor receptor tr10 |
| 03/20/2002 | EP1187838A1 Thiazolopyrimidines useful as tnf-alpha inhibitors |
| 03/20/2002 | EP1187836A1 Substituted imidazothiazoles as antidepressant agents |
| 03/20/2002 | EP1187834A1 Polymorphs of crystalline (2-benzhydryl-1-azabicyclo[2,2,2]oct-3-yl)-(5-isopropyl-2-methoxybenzyl)-ammoniumchloride as nk-1 receptor antagonists |
| 03/20/2002 | EP1187832A1 Amino heterocycles useful as pharmaceutical agents |
| 03/20/2002 | EP1187830A1 Process for the preparation of paroxetine and structurally related compounds |
| 03/20/2002 | EP1187827A1 Antiviral agents |
| 03/20/2002 | EP1187824A2 Novel (2-substituted-5 - 3-thienyl) -benzyl]- 2- ( 2-isopropoxy-5-fluoro] -phenoxy) -ethyl] -amine derivatives, method for the production and use thereof as medicaments |
| 03/20/2002 | EP1187822A1 Process for the preparation of 5-carboxphthalide and its use for the production of citalopram |
| 03/20/2002 | EP1187815A1 4-phenyl-pyrimidine derivatives |
| 03/20/2002 | EP1187814A2 5-phenyl-pyrimidine derivatives |
| 03/20/2002 | EP1187813A1 Azolylbenzamides and analogues and their use for treating osteoporosis |
| 03/20/2002 | EP1187810A2 Heterocyclic analgesic compounds and their use |
| 03/20/2002 | EP1187629A2 Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide |
| 03/20/2002 | EP1187627A2 Uses of h-trek-1 polypeptides and polynucleotides encoding them |
| 03/20/2002 | EP1187613A1 Amide substituted imidazoquinolines |
| 03/20/2002 | EP1187606A1 Pharmaceutical composition containing sibutramine and orlistat |
| 03/20/2002 | EP1187605A1 Non-malignant disease treatment with ras antagonists |
| 03/20/2002 | EP1187604A1 Compounds and methods for the treatment of post traumatic stress disorder |
| 03/20/2002 | EP1156040A4 2,4-dioxo-5-arylidenimino-1,3-pyrimidines |
| 03/20/2002 | EP1017696B1 Acidic addition salts of morphine alkaloids and the application thereof |
| 03/20/2002 | EP1009396B1 Pharmaceutical formulation comprising a 2-aminoacetamide derivative and an ion exchange resin |
| 03/20/2002 | EP0960110B1 3-ARYL SUBSTITUTED PYRAZOLO 4,3-d]PYRIMIDINE DERIVATIVES; CORTICOTROPIN-RELEASING FACTOR RECEPTOR (CRF 1?) SPECIFIC LIGANDS |
| 03/20/2002 | EP0888356B1 Condensed 2,3-benzodiazepine derivatives and their use as ampa-receptor inhibitors |
| 03/20/2002 | EP0642351B1 New pharmaceutical uses of krill enzymes |
| 03/20/2002 | EP0610475B1 Nerve-derived transglutaminase enzyme useful for inducing nerve regeneration |
| 03/20/2002 | CN1341111A 1-phenyl-4-(1-[2-aryl]cyclopropyl) methylpiperazines: dopamine receptor ligands |
| 03/20/2002 | CN1341102A Dopamine D1 receptor agonist compounds |
| 03/20/2002 | CN1341101A Phenyl-and pyridinyl derivatives |
| 03/20/2002 | CN1341100A 3-phenylpyridine derivatives and their use as nk-1 receptor antagonists |
| 03/20/2002 | CN1341099A 2-aminopyridines containing fused ring substituents |
| 03/20/2002 | CN1341095A Amide compounds for potentiation of cholinergic activity |
| 03/20/2002 | CN1341094A Monoamine reuptake inhibitors for treatment of CNS disorders |
| 03/20/2002 | CN1340350A Chewing medicine for treating facial paralysis and its preparing process |
| 03/20/2002 | CN1081068C Traditional Chinese medicine for treating ischialogia neuralgia |
| 03/20/2002 | CN1081062C Brain nutritious oral liquor and its preparation |
| 03/20/2002 | CN1081050C Drinking-stopping medicine |
| 03/20/2002 | CN1081042C Traditional Chinese medicinal composition for stopping drug taking and preparation process thereof |
| 03/20/2002 | CN1081034C Medicine of diguanidino-prine-hydride compounds for giving up drug-taking |
| 03/20/2002 | CN1081029C Sustained-release metal valproate tablets |
| 03/19/2002 | US6359146 Resolution of enantiomorph mixture |
| 03/19/2002 | US6359138 4-hydroxy-piperidine derivatives |
| 03/19/2002 | US6359130 Bridged indenopyrrolocarbazoles |
| 03/19/2002 | US6359112 Peptides used as agonists and/or inhibitors of amyloid formation and cytotoxicity and also for use in alzheimer's disease, in type II diabetes mellitus and in spongiform encephalophathies |
| 03/19/2002 | US6359011 Denaturants for sympathomimetic amine salts |
| 03/19/2002 | US6359005 Method for the treatment of mania and bipolar disorder |
| 03/19/2002 | US6358991 By administering indole compounds such as 1-(4-(2-azepan-1yl-ethoxy)-benzyl)-2-(4-hydroxy-phenyl)-3-methyl-1h-indol-5 -ol; epilepsy, asthma, eating disorders, obesity, neurodegenertive conditions, schizophrenia |
| 03/19/2002 | US6358990 Method for treating Alzheimer's disease |
| 03/19/2002 | US6358982 Heterocyclyl sulphonamide derivatives |